Publish in this journal
Journal Information
Vol. 55. Issue 9.
Pages 465-471 (September 2019)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 55. Issue 9.
Pages 465-471 (September 2019)
Original Article
DOI: 10.1016/j.arbr.2019.01.017
Is Endocan a Novel Diagnostic Marker for the Severity of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants?
¿Es el endocan un nuevo marcador diagnóstico de la gravedad de la displasia broncopulmonar en lactantes con muy bajo peso al nacer?
Visits
0
Cuneyt Taymana, Ufuk Cakira,
Corresponding author
drufukcakir@hotmail.com

Corresponding author.
, Cigdem Yucelb, Buse Ozer Bekmeza
a Division of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey
b Department of Biochemistry, Ankara Numune Training and Research Hospital, Ankara, Turkey
This item has received
0
Visits
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (1)
Table 1. Demographic And Clinical Characteristics Of The Groups.
Abstract
Introduction

Endocan levels were found to be associated with severity and mortality of the respiratory system diseases.

Objective

We aimed to figure out whether endocan was an important marker for the diagnosis, severity and follow-up of bronchopulmonary dysplasia (BPD).

Materials and methods

Infants with moderate/severe BPD, and who required hydrocortisone treatment were included in the study group. Infants without BPD were allocated in the control group. Endocan levels were compared between the control group and the study group, and before and after the treatment in the study group.

Results

A total of 148 infants, 74 infants in the control group and 74 infants in the BPD group, were included. The endocan level was higher in the BPD group than in the control group (P = .001). Endocan levels before treatment in the BPD group was found to be higher than endocan level after treatment (P = .021).

Conclusion

Our study found that endocan levels increased in moderate/severe BPD. Serum endocan levels may be a safe and novel indicator for the follow-up of response to treatment and the prognosis of the severity of the disease.

Keywords:
Esm1 protein
Premature
Infant
Bronchopulmonary dysplasia
Very low birth weight
Abbreviations:
BPD
PMA
ESM-1
VLBW
HC
NICU
BW
GA
C/S
NVD
RDS
PDA
IVH
NEC
ROP
CRP
IL-6
SPSS
SD
ROC
AUC
OSA
ARDS
Resumen
Introducción

Los niveles de endocan se han asociado con la mortalidad y la gravedad de enfermedades del aparato respiratorio.

Objetivo

El objetivo fue averiguar si el endocan es un marcador útil para el diagnóstico, la gravedad y el seguimiento de la displasia broncopulmonar (DBP).

Materiales y métodos

Se incluyeron en el estudio lactantes con DBP moderada/grave que requirieron tratamiento con hidrocortisona (grupo DBP). El grupo control lo constituyeron lactantes sin DBP. Los niveles de endocan se compararon entre el grupo control y el grupo de estudio y, en este último, tanto antes como después del tratamiento.

Resultados

Se incluyeron un total de 148 lactantes; 74 en el grupo control y 74 en el grupo DBP. Los niveles de endocan fueron más elevados en el grupo DBP que en el grupo control (p=0,001). Los niveles de endocan también resultaron superiores en el grupo DBP antes del tratamiento que después del mismo (p=0,021).

Conclusión

Nuestro estudio halló que los niveles de endocan se encuentran incrementados en la DBP moderada/grave. Los niveles séricos de endocan podrían utilizarse como un nuevo indicador seguro para el seguimiento de la respuesta al tratamiento y el pronóstico de gravedad de la enfermedad.

Palabras clave:
Proteína esm1
Prematuro
Lactante
Displasia broncopulmonar
Muy bajo peso al nacer

Article

These are the options to access the full texts of the publication Archivos de Bronconeumología (English Edition)
Member
If you are a member of SEPAR:
  • Go to SEPAR website and sign in.
  • Next go to "Biblioteca" section.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de Bronconeumología (English Edition)

Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Archivos de Bronconeumología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.